Skip to main content

Table 1 Patient characteristics

From: Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Characteristics N = 28 (%)
Age (years)
  median 66 (range: 50–80)
Stage
  De novo stage IV 7 (25)
  recurrent disease 21 (75)
Subtype
  HR+ HER2+ 28 (100)
  others 0
Number of treatment line
  median 6
  1 or 2 6 (21)
  3–6 9 (32)
  7–10 9 (32)
  > 10 4 (14)
Prior treatment for recurrent or metastatic breast cancer
  Trastuzumab 28 (100)
  Pertuzumab 4 (14)
  T-DM1 10 (36)
  Trastuzumab deruxtecan (T-DXd) 2 (7)
Visceral metastasis
  Yes 21 (75)
  No 7 (25)
Liver metastasis
  Yes 11 (39)
  No 17 (61)
Brain metastasis
  Yes 4 (14)
  No 24 (86)